Project Grant R37CA300110
Award Date 8/18/25
Completion Date 7/31/30
Dollars Obligated $673K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
- The National Cancer Institute (NCI) awarded a $858,166 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to The General Hospital Corporation (Massachusetts General Hospital) to conduct a randomized trial of a targeted palliative care intervention for patients with metastatic breast cancer. The study aims to improve documentation of end-of-life care preferences, delivery of end-of-life care, and patient-reported outcomes for this vulnerable population. The project...
- This Cooperative Agreement award of $675,867 from the National Cancer Institute (NCI), under the Federal Grant Program "Cancer Cause and Prevention Research" (CFDA 93.393), aims to increase the delivery of practical geriatric assessment in community oncology settings. The goal is to improve outcomes for older adult cancer patients (age 65+) who comprise 75% of the projected 22.2 million U.S. cancer survivors by 2030. The project will compare standard ASCO educational materials...
- This $1,073,982 National Cancer Institute project grant will fund research at Washington University in University City, Missouri from January 2023 through December 2027 under the Cancer Cause and Prevention Research program (CFDA 93.393). The research aims to document unmet social needs among 300 patient-caregiver dyads where the patient has breast or gynecologic cancer. It will analyze how social needs affect biopsychosocial outcomes for patients and caregivers, including depressive symptoms,...
- The National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), awarded a $817,829 project grant to The General Hospital Corporation (doing business as Massachusetts General Hospital) to test the efficacy of a virtual, resilience-based group program (SMART3RP-Lymphoma) for improving quality of life in post-treatment lymphoma survivors during the 0-2 year period following active cancer treatment. The 5-year project, which began on September 12, 2025, aims to...
- The National Cancer Institute (NCI) awarded a $168,500 Project Grant under the "Cancer Cause and Prevention Research" (CFDA 93.393) program to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida. The two-year grant, with an ultimate completion date of July 31, 2025, aims to evaluate physical and mental health symptoms (patient-reported outcomes) throughout the cancer diagnosis trajectory and their associations with cancer outcomes among HIV-positive...
- The National Cancer Institute (NCI) awarded a 5-year, $753,446 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to Boston Medical Center Corporation (BMC) to adapt and test an intervention to improve cervical cancer screening and follow-up in three diverse, underserved populations. The intervention combines education and quality improvement methods using performance improvement continuing medical education. It aims to decrease the overall burden of cervical...
- The National Cancer Institute (NCI) awarded a $2,452,400 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, Massachusetts. The grant, with an award date of April 1, 2025 and ultimate completion date of March 31, 2030, will fund a research program titled "Convergent Epigenetic Control of Diverse Neuroendocrine Cancers." The program aims to study the epigenetic and transcriptional states...
- The National Cancer Institute (NCI) awarded a $328,822 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to Implenomics Llcs, a minority-owned, women-owned small business located in Marblehead, Massachusetts. The grant, effective September 20, 2024 through August 31, 2026, will fund the development and pilot testing of the Integrated Cancer Awareness Network (ICAN), an innovative mHealth platform. ICAN will provide cancer risk, symptom, and screening education to...
- This $662,516 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research conducted by The General Hospital Corporation (doing business as Massachusetts General Hospital) to evaluate how fractionated radiation affects the tumor microenvironment and passive drug delivery in mouse and patient-derived models of locally advanced head and neck squamous cell carcinoma and anaplastic thyroid cancer. The research aims to quantify the impact of local...
- The federal Project Grant award of $637,596 from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) is for a research project titled "Interventions to Decrease Cancer Information Avoidance". The goal is to develop and test a video-based intervention designed to reduce defensive avoidance of colorectal cancer information and increase engagement, in order to improve screening rates among those who typically avoid such information (about 20% of the...